[Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
Donato M, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A.
Record ID 32018001457
Original Title: Inmunoglobulina en polineuropatía desmielinizante inflamatoria crónica y otras condiciones neurológicas
Authors' recomendations: CONCLUSIONS Moderate quality evidence indicates that immunoglobulin results in clinically significant improvements in the disability assessment scales used at short term, both in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy versus placebo. Low quality evidence suggests that immunoglobulin would not increase the results in the disability assessment score at six months in patients with distal demyelinating neuropathy with IgM paraprotein. Treatment with immunoglobulin is expensive and some cost-utility studies from high-income countries suggest that it would not be a cost-effective option. The clinical practice guidelines consulted recommend treatment with immunoglobulins in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy although they do not mention them in a specific order in relation to the available alternatives. In general, these guidelines do not make recommendations in relation to distal demyelinating neuropathy with IgM pararotein.
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Immunoglobulins, Intravenous
- Immunosuppressive Agents
- Motor Neuron Disease
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.